Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
ABSTRACTThe immunogenicity and safety of the concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine (Split Virion) (QIIV) in Chinese adults are unclear. In this open-label, randomized controlled trial, participants aged ≥ 18 years were recruited. El...
Main Authors: | Tao Huang, Jun Yu, Siyuan Zhang, Dewei Teng, Defang Dai, Yinbiao Zhu, Lidong Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2330770 |
Similar Items
-
Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
by: Viviane Gresset-Bourgeois, et al.
Published: (2018-01-01) -
Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
by: Sharad Agarkhedkar, et al.
Published: (2019-04-01) -
Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
by: Cecilia Montalban, et al.
Published: (2018-03-01) -
Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
by: Xiaoqiang Liu, et al.
Published: (2022-11-01) -
Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
by: David P. Greenberg, et al.
Published: (2017-09-01)